Sangamo Partners With Biogen to Target Alzheimer’s and Parkinson’s Development24/7 Wall Street • 02/27/20
Biogen and Sangamo Announce Global Collaboration to Develop Gene Regulation Therapies for Alzheimer’s, Parkinson’s, Neuromuscular, and Other Neurological DiseasesGlobeNewsWire • 02/27/20
Biogen Stock Recently Broke Out On A Patent Win — Should You Buy Shares?Investors Business Daily • 02/20/20
Why Biogen Fits Well With Warren Buffett and Berkshire Hathaway, Even With Biotech Risks24/7 Wall Street • 02/18/20
Will Biogen’s Big Patent Victory Ease Investor Worries About Its Alzheimer’s Drug?The Motley Fool • 02/11/20
Pharma Giants Slide On Alzheimer's Failures — Taking Biogen With ThemInvestors Business Daily • 02/10/20